Reata Pharmaceuticals (RETA) Scheduled to Post Earnings on Thursday

Reata Pharmaceuticals (NASDAQ:RETA) is set to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Reata Pharmaceuticals to post earnings of ($0.97) per share for the quarter.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings results on Thursday, February 28th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.16. The company had revenue of $8.45 million for the quarter, compared to analyst estimates of $6.60 million. On average, analysts expect Reata Pharmaceuticals to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of NASDAQ:RETA traded up $0.43 during trading on Tuesday, reaching $85.48. 89,215 shares of the company’s stock traded hands, compared to its average volume of 153,894. Reata Pharmaceuticals has a fifty-two week low of $25.17 and a fifty-two week high of $104.53. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 5.23. The stock has a market capitalization of $2.53 billion, a PE ratio of -29.78 and a beta of 2.91.

RETA has been the topic of a number of analyst reports. ValuEngine upgraded Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. BidaskClub upgraded Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $100.00 target price on shares of Reata Pharmaceuticals in a research report on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $100.33.

In related news, insider Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $90.17, for a total value of $180,340.00. Following the completion of the sale, the insider now owns 4,138 shares in the company, valued at approximately $373,123.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jason Douglas Wilson sold 4,000 shares of Reata Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $83.82, for a total transaction of $335,280.00. Following the completion of the sale, the chief financial officer now owns 4,000 shares of the company’s stock, valued at approximately $335,280. The disclosure for this sale can be found here. Insiders have sold a total of 44,227 shares of company stock worth $4,093,386 over the last 90 days. Insiders own 31.69% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2019/05/07/reata-pharmaceuticals-reta-scheduled-to-post-earnings-on-thursday.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Featured Article: Trading Options- What is a Strangle?

Earnings History for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.